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Abstract
Purpose of Review Psychiatry is steadily moving toward a
new conceptualization of brain disorders that blurs long-
held diagnostic distinctions among neurodevelopmental
and psychiatric conditions, including autism. Genomic
discoveries are driving these changing perceptions, yet
there has so far been minimal impact on traditional genetic
counseling practices that continue to view autism through
the lens of a dichotomous, all-or-none risk model.
Recent Findings High rates of comorbidity exist across
autism spectrum disorder, schizophrenia, intellectual dis-
ability, and other brain-based disorders. Recent epidemio-
logical studies have shown that co-occurrence of
neurodevelopmental and psychiatric disorders is the rule,
rather than the exception, in affected individuals and within
families. Moreover, studies of chromosomal microarray
analysis and whole exome sequencing have now detected
many of the same pathogenic copy number and sequence-
level variants across cohorts with different clinical
presentations.
Summary Going forward, the genetic counseling field will
need to significantly adapt its approaches to pedigree
interpretation, variant analysis, and patient education to
more precisely describe both the chance and the nature of
autism recurrence in terms of a continuum of brain dys-
function. These efforts will have implications for multiple
practice areas and require philosophical changes for
experienced practitioners and for the training of new
genetic counselors. Resetting entrenched dichotomous
notions about autism and other brain-based manifestations
of genetic conditions will require a strategic educational
effort on the part of the genetic counseling profession.
Keywords Autism spectrum disorder  Genetic counseling 
Schizophrenia  Intellectual disability  Copy number 
Pathogenic variant  Chromosomal microarray  Whole
exome sequencing
The ‘‘genetics of autism’’ is thus neither singular nor separable from the
‘‘genetics of intellectual disability,’’ the ‘‘genetics of schizophrenia,’’ or
the ‘‘genetics of epilepsy.’’ The more general term of ‘‘developmental
brain dysfunction’’ has been proposed to encompass disorders arising
from altered neural development, which can manifest clinically in diverse
ways.
Kevin J. Mitchell
(The Genetics of Neurodevelopmental Disorders, 2015) [1]
Introduction
When first described as a childhood-onset psychiatric
condition over 70 years ago, autism was considered a rare
disorder of unknown etiology. Leo Kanner originally
reported on 11 children with communication disturbances,
a relative lack of motivation for social and emotional
interaction, and preference for an excessive degree of
routine and ‘‘sameness’’ in their environments [2]. Over the
next few decades, autism was widely regarded as a type of
childhood schizophrenia (SCZ), and some theorized that it
was a form of psychotic withdrawal in response to an
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emotionally cold and distant mother [3•]. By the 1970s, a
more enlightened understanding of autism as a biologically
based condition began to emerge. Recent decades have
seen the refinement of diagnostic criteria for autism, as
well as the parsing out and later recombining of autism
subtypes under the current umbrella of autism spectrum
disorder (ASD) [3•, 4, 5].
ASD is a complex, chronic neurodevelopmental disorder
that is clinically and etiologically heterogeneous, yet
highly heritable, with a recent meta-analysis of twin studies
suggesting heritability estimates from 64 to 91 % [6]. The
genetic architecture of ASD includes rare pathogenic copy
number variants (CNVs) and single nucleotide variants
(SNVs), in addition to inherited background polygenic risk
[7–9]. By a ratio of *4.5 to 1, boys are more commonly
affected by ASD than girls, leading to speculation about
female protective effects as well as genetically conferred
male vulnerabilities [10–14, 15•].
The much publicized increase in ASD prevalence over
the past three decades has been well-documented in public
health surveillance studies, with the most recent large-scale
report showing a steady rate of ASD of 1 in 68 children in
the US between 2010 and 2012 [16]. The extent to which
there has been a true increase in ASD incidence, versus the
collective effects of diagnostic and ascertainment changes,
continues to be debated [17–20]. There is substantial evi-
dence that non-etiological factors, such as ‘‘diagnostic
substitution’’ [i.e., intellectual disability (ID) diagnoses
decreased at the same time ASD diagnoses increased], have
played a role. However, not all of the ‘‘autism epidemic’’
can be explained by these factors, and research efforts
continue to investigate genetic, environmental, and other
potential contributors [17–22].
Deliberations about clinical diagnostic criteria for
ASD have largely played out within the fields of pedi-
atric psychiatry and psychology, with relatively little
cross-fertilization from research efforts to uncover its
biological basis. Recent genomic evidence has shed new
light on the interconnectedness of many brain-based
pediatric and adult-onset psychiatric conditions, including
ASD, ID, and SCZ, at the same time revealing biological
inconsistencies with clinical diagnoses defined by psy-
chiatry’s Diagnostic and Statistical Manual of Mental
Disorders (DSM) [4]. The discovery of linked genetic
underpinnings among several DSM-based conditions has
led to emerging new perspectives on diagnosis, inter-
ventions, and research strategies for ASD [23, 24•, 25•].
This evolving conceptualization of autism as one con-
stellation of symptoms within a larger universe of
interconnected brain dysfunction has the potential to
radically change genetic counseling for neurodevelop-
mental and psychiatric disorders.
Autism as Developmental Brain Dysfunction
(DBD)
Recently, the long-standing practice of defining ASD and
other psychiatric diagnoses based on dichotomous, all-or-
none symptom constellations (e.g., autism vs. no autism)
has been called into question [23, 24•, 26]. Some individ-
uals exhibit behavioral features of autism, for example,
without fully meeting the criteria for an ASD diagnosis.
Moreover, high rates of comorbidity exist across ASD,
SCZ, ID, and other brain disorders; and epidemiological
studies have shown that co-occurrence of neurodevelop-
mental and psychiatric disorders is the rule, rather than the
exception, in affected individuals and within families.
ASD, ID, SCZ, attention deficit/hyperactivity disorder
(ADHD), epilepsy (EP), and bipolar disorder (BPD), for
example, have long been conceptualized as clinically dis-
tinct entities but have overlapping symptoms, high rates of
co-occurrence, etiologic heterogeneity, and shared risk
factors; sometimes different disorders cluster within the
same families [24•]. It has become increasingly clear that
the genome does not respect psychiatry’s clinical diag-
nostic boundaries; chromosomal microarray analysis
(CMA) and whole exome sequencing (WES) studies have
now detected many of the same pathogenic CNVs and
SNVs across cohorts with different clinical presentations,
as illustrated in Table 1 [27–36]. It has been proposed that
neurodevelopmental and psychiatric diagnoses should not
be viewed as causally and pathophysiologically distinct,
but as the consequences of DBD, a common denominator
that reflects altered neural development which can manifest
clinically in diverse ways [24•, 37].
DBD represents a group of developmental, neurological,
and psychiatric conditions characterized by cognitive,
behavioral, language, motor, and other brain-based func-
tional impairments [24•]. Rather than dichotomous, all-or-
none disorders, ASD, ID, ADHD, SCZ, and other DBD are
now thought to reflect varying degrees of dysfunction along
a broad continuum of measurable (quantitative) human
traits, including intelligence, social responsiveness, atten-
tion, language abilities, motor skills, and imaginative
thought. All humans fall somewhere along the continuum
of function for these quantitative traits, with diagnoses such
as ASD representing the extreme end of a spectrum where
function is impaired to the degree that it warrants a clinical
label. Current opinions from top researchers in the field and
by the US National Institutes of Mental Health suggest that
ASD and other DBD can best be studied and conceptual-
ized through quantitative behavioral and cognitive
research, irrespective of artificially defined clinical diag-
nostic boundaries [23, 24•]. An important corollary is that
DBD candidate gene discovery can be maximized by
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combining datasets from different neurodevelopmental and
psychiatric disorders [28]. This changing conceptualization
of autism and its interconnectedness with other DBD, and
with the continuum of ‘‘normal’’ human behavior, has
direct implications for pedigree interpretation, variant
analysis, and risk assessment.
Genetic Evaluation of ASD
Children with autism and other neurodevelopmental con-
cerns represent a significant percentage of referrals for
clinical genetics evaluation, with etiological investigation
being the primary indication. As in other areas of medical
practice, genetic testing for individuals with ASD has
moved beyond the purview of clinical genetics and is being
ordered by developmental pediatricians, neurologists,
psychiatrists, and other specialists, as well as by primary
care providers. Pediatric genetic counselors therefore see
children with ASD referred through a variety of portals and
having undergone various degrees of genetic diagnostic
work-up. Prenatal genetic counselors routinely field
inquiries about ASD recurrence from expectant couples
with a previous affected child, or more commonly, a family
history of ASD. Within their growing specialty area, psy-
chiatric genetic counselors increasingly encounter adults
with mental illness who report autism symptoms in them-
selves and/or other family members. Additionally, a
growing army of research and laboratory-based genetic
counselors is employed on the front lines of variant inter-
pretation for genes implicated in ASD. Thus, the impact of
the theoretical ‘‘sea change’’ about ASD’s connections to
other neurodevelopmental disorders, and to adult-onset
psychiatric conditions, has direct relevance across several
different areas of genetic counseling practice.
Prior to the advent of array and whole genome/exome
sequencing technologies, genetic contributors to ASD were
largely unknown, and genetic counseling focused on empiric
recurrence risks for ASD, occasionally informed by a posi-
tive pedigree. Consensus guidelines from national profes-
sional organizations, including the American College of
Medical Genetics, the National Society of Genetic Coun-
selors, and the American Academy of Pediatrics, recom-
mend consideration of fragile X and CMA for children
diagnosed with ASD [38–41], and increasingly, clinical
WES is being ordered as a standard part of the etiological
evaluation of neurodevelopmental disorders. Although
specific genetic causes are individually rare in ASD, they
collectively represent its most significant known etiology
[8, 15•, 28, 42]. Whole genome CMA reveals a pathogenic
CNV in 15–20 % of individuals with unexplained develop-
mental delay, ID, ASD, or multiple congenital anomalies
[43, 44]. The reported yield is 7–14 % in studies restricted to
the evaluation of individuals with ASD [45–50]. Large lab-
oratory-based clinical WES studies have consistently iden-
tified a pathogenic SNV in 26–29 % of people with
neurodevelopmental disorders in general [51–53], including
8–20 % of those with ASD [50, 52, 53]. Among children
with ASD who underwent both CMA and WES testing, the
combined molecular diagnostic yield was 15.8 % [50].
When a specific cause can be identified for ASD, genetic
counseling has traditionally followed familiar processes
with regard to risk assessment, explanations of inheritance,
recommended family testing, anticipatory medical guid-
ance, and discussion of psychosocial aspects of genetic
disorders. For well-known genetic causes of ASD, such as
fragile X syndrome, there may be an abundance of
resources and established support organizations for the
family. More commonly, however, little is known about the
genetic diagnosis, as is the case for the large number of
newly identified rare, pathogenic CNVs and SNVs impli-
cated in autism. These include pathogenic microdeletions
of 15q11.2 and loss of function variants in NRXN1 that can
cause ASD but also confer risk for a wide range of other
neurodevelopmental and psychiatric diagnoses, from ID to
SCZ, and are found as well in seemingly unaffected
Table 1 Variable expressivity of the pathogenic recurrent copy
number variants and single nucleotide variants most commonly
identified in ASD cohorts
ASD ID/DD EP SCZ
CNV
16p11.2 deletion X X X
16p11.2 duplication X X X X
15q11.2-q13.1 (BP2–BP3) duplication X X X X
15q13.2-q13.3 (BP4–BP5) deletion X X X X
1q21.1 duplication X X X X
22q11.2 duplication X X X
16p13.11 deletion X X X X
7q11.23 duplication X X X
16p12.2 deletion X X X X
17q12 deletion X X X X
SNV
NRXN1 X X X X
CTNNA3 X X X X
CHD8 X X X X
SCN2A X X X
ADNP X X X
PTEN X X X
SCN1A X X X
SHANK3 X X X X
DYRK1A X X X
SYNGAP1 X X X X
References [24•, 28, 33–36]
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individuals [34, 36, 50, 51, 54]. With few exceptions, the
phenotypic effects of this recent generation of CMA and
WES-detected etiologies of autism are nonsyndromic,
meaning that they do not induce structural organ defects,
overt dysmorphic features, or significant medical comor-
bidities. For these newly identified causes, genetic coun-
seling relies heavily on variant analysis and pedigree
interpretation and requires a broader discussion of neu-
rodevelopmental and psychiatric risk beyond a family’s
focused concern about autism. This represents a marked
departure from the traditional model of genetic counseling
in which ASD is described as one specific characteristic
among a syndrome’s physical and medical features [25•].
The DBD Pedigree
A hallmark of genetic counseling practice is the ability to
construct a detailed family pedigree in order to inform
genetic risk assessment. When a consistent physical trait is
present, as in families with multigenerational cystic kidneys,
for example, a pedigree serves as a visual shorthand that
allows the genetic counselor to quickly deduce an inheri-
tance pattern. For neurodevelopmental and psychiatric
phenotypes, these patterns are not quite so straightforward
and often obscured by artificial diagnostic distinctions,
masking the true magnitude of DBD recurrence. In medical
genetics, ASD, EP, BPD, cerebral palsy, and other DBD are
still widely and incorrectly viewed as unrelated conditions,
each one designated with its own distinct symbol or colored
quadrant in a pedigree to emphasize their presumed lack of
connection to each another [25•]. Likewise, recurrence
estimates for ASD have historically been based on single-
minded analyses of repeated instances of ASD (vs. no ASD)
in families, despite the eagerness of parents to point out an
uncle with obsessive compulsive disorder or a sibling with
significant language impairment. Once dismissed as irrele-
vant, the importance of these seemingly unrelated diagnoses
in other relatives is now being appreciated and forcing a
reexamination of the long-held genetic tenets of nonpene-
trance and variable expressivity, at least in terms of neu-
ropsychiatric phenotypes [24•, 25•, 54].
Studies published in the last decade suggest that the
empiric risk for recurrence of idiopathic ASD hovers
around 10 % (range *7 to 14 %) for couples with one
affected child [55–59, 60•], but may be as high as 32–36 %
for couples who already have two or more children with
idiopathic ASD [57, 61]. Only recently have studies begun
to connect the dots between autism and different types of
DBD, and the recurrence risk for any type of DBD in
families with one ASD proband is far higher than previously
imagined [60•]. For example, in a large Finnish epidemio-
logic study involving thousands of families, the prevalence
of ASD among siblings of probands with ASD was 10.5 %,
but almost 37 % of these siblings had some type of neu-
rodevelopmental or psychiatric disorder (vs. 17.4 % of
controls) [60•]. Specifically, the risk among siblings was
significantly increased for tic disorder, ADHD, ID, learning
or coordination disorder, conduct or oppositional disorder,
childhood-onset emotional disorder, SCZ spectrum disor-
der, affective disorder, and anxiety disorder [60•]. Recur-
rence risks for siblings were similar whether or not the
proband had ID and irrespective of proband gender. Much
smaller studies have suggested that 20–25 % of siblings
who do not meet criteria for ASD have a history of language
impairment or delay [56, 62]. It is increasingly apparent that
the traditional pedigree designating ASD, ID, and other
DBD as distinct and unrelated conditions in a family is
fundamentally flawed. Likewise, recurrence risk estimates
that address only the isolated chance for ASD without ref-
erencing the significantly higher chance for other DBD can
no longer be considered acceptable.
Families who seek genetic counseling about autism are
generally unaware of its newly discovered cross-connec-
tions with other DBD. Traditionally, genetic counselors list
ASD, along with a condition’s other known physical and
behavioral traits, and cite its relative chance of occurring as
part of the disorder [25•]. While a syndrome’s physical
manifestations can be accurately described in an all-or-
none, categorical way (e.g., 75 with vs. 25 % without a
congenital cardiac defect), the same is not true of behav-
ioral and cognitive symptoms. For example, approximately
15 % of children with a 22q11.2 deletion meet behavioral
criteria for an ASD diagnosis [63]. A parent might easily
assume that 85 % of those with a 22q11.2 deletion are
completely unaffected by ASD, not appreciating that aut-
ism symptoms occur along a continuum that extends
beyond the black and white cutoff for a clinical ASD
diagnosis. Describing the prevalence of a syndrome’s
neurodevelopmental and psychiatric diagnoses in the same
breath as congenital anomalies is misleading and fails to
convey the continuously distributed nature of brain-based
symptoms. Whether the etiology is unknown, due to a well-
defined syndrome, or associated with a poorly understood
genomic variant, the recognition that ASD is etiologically
tethered to a host of other brain disorders and to the con-
tinuum of ‘‘normal’’ human behavior is forcing a reexam-
ination of genetic counseling approaches. So far, clinical
genetics professionals have paid relatively little attention to
the seismic changes occurring in the fields of psychiatry
and developmental medicine that will ultimately have a
major impact on how autism and other brain disorders are
defined, described, and treated [5, 24•, 26, 64–66].
‘‘Reinventing’’ genetic counseling practices related to these
disorders will arguably be one of the most important
challenges facing the profession over the coming decade.
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Conclusions
Psychiatry is steadily moving toward a new conceptual-
ization of brain disorders that blurs long-held diagnostic
distinctions among neurodevelopmental and psychiatric
conditions, including autism. Genomic discoveries lie at
the heart of these changing perceptions, yet there has so far
been minimal impact on traditional genetic counseling
practices that continue to view ASD through the lens of a
categorical, all-or-none risk model. Going forward, the
genetic counseling field will need to significantly adapt its
approaches to pedigree interpretation, variant analysis, and
patient education to more precisely describe both the
chance and the nature of autism recurrence in terms of a
broader DBD continuum. These efforts will have impli-
cations for multiple practice areas and require philosophi-
cal changes for experienced practitioners and for the
training of new genetic counselors. Resetting entrenched
dichotomous notions about autism, ID, and other brain-
based manifestations of genetic conditions will require a
strategic educational effort on the part of the genetic
counseling profession. Once accomplished, families seek-
ing genetic counseling will benefit from a more accurate
and contextual understanding of these disorders on which
to base informed decisions.
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